Literature DB >> 10569658

Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group.

J J Blanc1, C Voinov, M Maarek.   

Abstract

In patients with recent-onset atrial fibrillation (AF), restoration of sinus rhythm is considered to be the first-line therapeutic option. Although this conversion might be obtained by direct-current shock or intravenous antiarrhythmic drugs, administration of an oral loading dose of class I or III antiarrhythmic drugs is more simple and convenient. This prospective, randomized, multicenter study compares the time to conversion to sinus rhythm obtained with an oral loading dose of propafenone or amiodarone. Patients with recent-onset AF (<2 weeks), without contraindications for the 2 drugs, were randomly assigned to be treated with propafenone (600 mg for the first 24 hours and if necessary a repeated dose of 300 mg for 24 hours) or amiodarone (30 mg/kg for the first 24 hours and if necessary a repeated dose of 15 mg/kg for 24 hours). Exact conversion time during the first 24 hours was determined by Holter monitoring. In each treatment group 43 patients with the same baseline characteristics were included. The median time for restoration of sinus rhythm was shorter (p = 0.05) in the propafenone (2.4 hours) than in the amiodarone (6.9 hours) group. After 24 hours (56% in the propofenone and 47% in the amiodarone group) and 48 hours, the same proportion of patients in the 2 groups recovered sinus rhythm (no serious adverse events were noticed). Thus, oral loading dose of propafenone or amiodarone was safe with a similar conversion rate of recent-onset AF. Propafenone had a faster action.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569658     DOI: 10.1016/s0002-9149(99)00493-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment.

Authors:  Giuseppe Boriani; Cristian Martignani; Mauro Biffi; Alessandro Capucci; Angelo Branzi
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation.

Authors:  Omar F Hassan; Jassim Al Suwaidi; Amar M Salam
Journal:  J Atr Fibrillation       Date:  2013-06-30

Review 3.  Atrial fibrillation (acute onset).

Authors:  Gregory Y H Lip; Stavros Apostolakis
Journal:  BMJ Clin Evid       Date:  2014-11-27

Review 4.  Atrial fibrillation (acute onset).

Authors:  Gregory Y H Lip; Stavros Apostolakis
Journal:  BMJ Clin Evid       Date:  2011-02-15

5.  Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation.

Authors:  G Nichol; F McAlister; B Pham; A Laupacis; B Shea; M Green; A Tang; G Wells
Journal:  Heart       Date:  2002-06       Impact factor: 5.994

Review 6.  Pharmacological cardioversion of atrial fibrillation: current management and treatment options.

Authors:  Giuseppe Boriani; Igor Diemberger; Mauro Biffi; Cristian Martignani; Angelo Branzi
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Pharmacological Cardioversion of Atrial Tachyarrhythmias Using Single High-Dose Oral Amiodarone: A Systematic Review and Meta-Analysis.

Authors:  Lucy Y Lei; Derek S Chew; William Lee; Ziran Meng; Erkan Ilhan; Raffaello Furlan; Robert S Sheldon; P Timothy Pollak; Satish R Raj
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-11-22

Review 8.  [Pharmaceutical treatment of atrial fibrillation].

Authors:  Anil-Martin Sinha; Johannes Brachmann; Martin Schmidt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-07-13

Review 9.  Atrial fibrillation (acute onset).

Authors:  Gregory Y H Lip; Timothy Watson
Journal:  BMJ Clin Evid       Date:  2008-05-02

Review 10.  New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.

Authors:  Stanley Nattel; Paul Khairy; Denis Roy; Bernard Thibault; Peter Guerra; Mario Talajic; Marc Dubuc
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.